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Abstract 
Rising health care costs and increasing demands for health care, requires techniques 
to choose between competing uses and even rationing of health care. Economic 
evaluations and health technology assessments are increasingly a means to assess 
the cost effectiveness of health care interventions so as to inform such resource 
allocation decisions.  
To date, the adoption of health technology assessments, as a way of assessing cost 
effectiveness, in ophthalmology has been slower, relative to their implementation in 
other specialities. Nevertheless demands for eye services are increasing due to an 
aging population.  The prevalence of conditions such as glaucoma, cataract, diabetic 
eye disease, age related macular degeneration increase with age and it is predicted 
that global blindness will triple by 2050. So there is a challenge for ophthalmologists 
to ensure that they can contribute to, interpret, critically evaluate, and use findings 
from economic evaluations in their clinical practice. To aid this, this article serves as a 
primer on the use of health technology assessments to assess cost effectiveness 
using economic evaluation techniques for ophthalmologists. 
The challenges facing health care systems worldwide - changing demographics 
evolution of new technologies are only going to intensify. With this in mind, 
ophthalmology needs to be ready and able to engage with health economists to 
prepare, interpret, critically evaluate and use findings of economic evaluations and 
health technology assessments. 
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Introduction 
Health systems globally face many challenges that contribute to rising health care 
costs. In developed countries, growing ageing populations which place increasing 
demands on all health care services forms one such challenge. Eye care services are 
no exception owing to the increased prevalence of conditions such as glaucoma, 
cataract, diabetic eye disease, age related macular degeneration and others amongst 
those in older age groups. The number of people with blindness and vision impairment 
is increasing owing to global population growth, coupled with changing age structures, 
and it is anticipated that global blindness will triple by 2050 [1]. Specifically, given 
population growth estimates for those over 65 years old the demand for ophthalmology 
services is anticipated to increase by 5% annually [2]. This rise in health care 
expenditure will not replace other health care spending but rather contribute to rising 
total health care expenditure [3].  
While vision interventions provides some of the largest returns on investment [4], 
meeting these health care demands requires resources that in health care are 
notoriously scarce. The unlimited demands for limited resources means choices must 
be made and services are often rationed as a result. Economic evaluations and health 
technology assessments are increasingly used a means to assess the cost 
effectiveness of health care interventions so as to inform resource allocation decisions.  
The pace at which health technology assessments as a way of assessing cost 
effectiveness have been employed in ophthalmology has been slower relative to their 
implementation in other specialities [5]. Nevertheless, there have been modest 
increases in the incorporation of health economics in ophthalmology. In 2008 the 
European Glaucoma Society reported less than 700 ‘hits’ in PubMed when the 
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following search terms were searched with glaucoma; ‘cost’, ‘resource’, ‘cost-
effectiveness’ and ‘cost-utility’. Repeating this exercise in 2017 yields almost 1100 
‘hits’ in PubMed. Many of these studies only examine costs however and so are not 
full economic evaluations. This concern has been highlighted previously [5, 6]. Further 
analysis of search terms on PubMed, considering glaucoma, cataract, diabetic 
retinopathy and macular degeneration confirms little has changed.  There are 3,616 
‘hits’ for these four conditions and cost, resource, cost effectiveness or cost utility 
between 1966 and June 2017.  Of these, 50% were published since 2008. Only 27% 
were for articles incorporating cost effective or cost utility analyses. See Table 1. 
A steep learning curve is thus anticipated as rationing health care continues to 
dominate public policy formation, health insurers continue to scrutinize claims and out 
of pocket payments rise for patients. There exists then a challenge for 
ophthalmologists to ensure that they can contribute to, interpret, critically evaluate [7], 
and use findings from economic evaluations in their clinical practice. To aid this, this 
article serves as a primer on the use of health technology assessments to assess cost 
effectiveness using economic evaluation techniques for ophthalmologists.  
 
Defining Economic Evaluations 
Health technology assessments involve examining the medical, economic, social and 
ethical implications of the development, use and diffusion of a health care intervention 
or technology. Economic evaluation techniques provide a framework for considering if 
the benefits accruable from an intervention are worth its costs [8]. Health technology 
assessments are increasingly being used worldwide as a means of assessing the 
costs and consequences of competing interventions and thereby informing decisions 
 6 
regarding which interventions, services, programmes, technologies etc. to finance 
and/or deliver. In deciding between competing interventions such a systematic 
approach is needed.  
When conducting an economic evaluation, availability, efficacy, effectiveness and 
efficiency should be considered. Availability determines whether the intervention is 
accessible to those who need it and who could benefit from it [9]. Efficacy confirms 
that the intervention works and does more good than harm [9]. Effectiveness describes 
the success with which the intervention works in real life non-ideal circumstances [9]. 
Efficiency, by examining the relationship between resource inputs and outputs 
assesses to what degree the intervention represents value for money.  
Types of Economic Evaluation 
To conduct a full economic evaluation there must be at least one alternative or 
comparator and both the benefits and costs must be examined. If these two criteria 
are not met the evaluation is a partial evaluation. For example, if only the costs of an 
intervention and current treatment are considered it is a cost analysis.  
There are four types of full economic evaluation; Cost Minimisation Analysis (CMA), 
Cost Benefit Analysis (CBA), Cost Effectiveness Analysis (CEA) and Cost Utility 
Analysis (CUA). In each, costs are measured in monetary amounts and the difference 
between them lies in how the benefits are measured.  
CMAs are uncommon, as they require that the accruing benefits from each of the 
interventions under consideration are equivalent. The intervention that delivers with 
the least cost is then recommended. Complete equivalence between interventions is 
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rare and as and so economic evaluations which focus on estimating both cost and 
effect differences are advocated [10]. 
In CBAs the ‘benefits’ - changes in welfare, are measured in monetary units. As both 
the benefits and costs are measured in monetary amounts the net benefit can be 
estimated; Net Benefit = Benefits – Costs. If net benefit is positive i.e. benefits exceed 
costs, the intervention is considered cost effective. If the net benefit is negative i.e. 
costs exceed benefits, the intervention cannot be considered cost effective. Estimating 
health outcomes in monetary units is however challenging. 
In CEAs the benefits of an intervention are expressed in natural health units such as 
life-years gained, symptom free days or days of disability avoided etc. A disadvantage 
is that CEAs can only be used to compare interventions that produce a common health 
effect.  
In light of this CUAs emerged. Herein the benefits are measured using a measurement 
that represents quality of life – Quality Adjusted Life Years for example.  
In both CEA and CUA the incremental costs of the intervention and comparator are 
compared to the incremental benefit using a Cost Effectiveness Ratio; (Cost 
Intervention - Cost Comparator) / (Benefits Intervention - Benefits Comparator). If the 
intervention is less costly and more effective i.e. generates more benefit than the 
comparator, it can be considered cost effective. Alternatively, if the intervention is more 
costly and less effective than the comparator it cannot be considered cost effective. If 
the intervention is more costly and more effective an estimate of what society is willing 
to pay for the additional unit of effectiveness is required to determine if the additional 
benefit is worth the additional cost.  
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Conducting an Economic Evaluation 
As before, for an economic evaluation to be a full economic evaluation a comparator 
is needed. This represents an appropriate alternative to the intervention or technology 
under consideration. Usually the comparator is typical or usual care. For novel 
interventions, technologies or programmes the comparator may be more simply to ‘do 
nothing’. 
The perspective for the evaluation then needs to be considered. Given the foundation 
of economic evaluations is welfare economics, economic evaluations should, in 
theory, be undertaken from a societal perspective. However, as evaluations are often 
requested or commissioned by health payers theirs is often the only perspective 
sought. This is considerably narrower than a societal perspective and risks excluding 
relevant benefits and costs accrued, some of which may be to the patient, so caution 
should be exercised. 
Estimating Costs and Benefits for Economic Evaluation 
When estimating costs all relevant resources associated with the intervention and its 
comparator need to be identified, measured and valued [9]. Costs occurring in the 
future will need to be discounted to account for time preference. Applying a discount 
rate has the effect of giving less weight to benefits and costs occurring in the future. 
National guidelines should be consulted for instructions on which discount rate to use, 
calculating depreciation on assets, associated labour costs, overhead and exchange 
or inflation rate calculations as required. Relevant overheads should also be included.  
When estimating benefits the methods used depend on the type of economic 
evaluation being employed. In CBAs, benefits, reflecting changes in welfare, are 
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measured in monetary amounts, which can be measured by a variety of means. The 
equivalent variation method estimates the income adjustment necessary to reflect 
changes in consumer utility that would occur if an event, for example blindness, 
occurred. The compensating variation method estimates the income adjustment that 
returns the consumer to the original utility after an event has occurred. Willingness to 
pay techniques estimate the maximum amount that an individual would be willing to 
sacrifice so as to achieve a desired state of health or to avoid an undesirable state of 
health. Each of these methods requires extensive data collection and are, as a result, 
under-utilized in health technology assessment. 
Much of the empirical literature for economic evaluations and/or health technology 
assessments employ CEAs wherein benefits are measured as natural health units or 
CUAs wherein benefits are measured using utility measurements such as Quality 
Adjusted Life Years. The latter are used predominantly in the United Kingdom, other 
European countries and Canada, who have determined willingness to pay estimates 
for units of effectiveness and advocate their use. Here, generic preference based 
instruments that measure health related quality of life such as the EQ-5D developed 
by EuroQol are advocated. Alternatively condition specific measures, such as the 
National Eye Institute 25-item visual function questionnaire (VFQ-25), may be used 
and mapped onto generic preference based instruments to generate QALYs, using 
bespoke algorithms.  The VFQ-25 is a 25-item version of the 51-item National Eye 
Institute Visual Function Questionnaire (NEI-VFQ), developed with the goal of creating 
a survey that would measure the dimensions of vision targeted health that are most 
important for persons who have chronic eye diseases  [11]. 
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As with costs, benefits accruing in the future need to be discounted to account for time 
preference using appropriate discount rates. Again, national guidelines typically detail 
instructions for discounting.  
Identifying Evidence  
Evidence for benefit and cost estimates of interventions and comparators may be 
readily available to populate an economic model, if the economic evaluation is being 
conducted alongside a clinical trial, for example. However, it is often the case that 
evidence from a variety of sources will need to be gathered and extrapolated into the 
future to consider all relevant comparators for a relevant time period. As a result the 
use of Decision Analytical Modelling to complement Economic Evaluations has 
evolved [12, 13].  
Decision Analytical Modelling 
Decision Analytical Modelling employs quantitative methods to systematically examine 
the clinical, epidemiological and economic evidence of an intervention and its 
comparator. This generates a precise point estimate for the benefits and costs as well 
as enabling an examination of the uncertainty surrounding the decision under review 
and its outcome [14].  
Decision Analytical Modelling can be used to extrapolate beyond time points observed 
in a trial, link intermediate endpoints to final outcomes; generalize outcomes to other 
settings and synthesize comparisons between alternatives where trials are non-
existent  [12]. 
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While no amount of modelling can fully offset the gaps in available evidence, decision 
analytical modelling can provide point estimates for economic evaluations and permit 
valid statistical analysis of data to inform such evaluations [9, 12]. 
While there are many types of decision analytical models, the simplest and most 
common are decision trees. These graphically represent the ‘prognosis’ of alternative 
interventions using pathways. They are useful for simple models (no time dependency 
for example), with short time horizons or multifaceted value structures [9, 15, 16]. State 
transition models are also popular. Decision problems are conceptualized in terms of 
a set of health states and transitions between those states for a particular condition. 
The most common type of state transition model employed is a Markov Model [14]. 
These represent random processes that occur over time using cycles [17] and are 
useful for handling disease complexities and managing benefits and costs 
simultaneously, as well as facilitating the estimation of QALYs [17, 18] and cohort 
simulations. 
Handling Uncertainty 
In every economic evaluation and its decision analytical model when used, uncertainty 
exists. Uncertainties are costly and increase the risk of making incorrect 
recommendations regarding the cost effectiveness of an intervention. This can exert 
costs on society owing to exposure to interventions that are later demonstrated to be 
ineffective and/or delayed access to beneficial treatments/programmes. Reversing 
incorrect decisions is also costly. Thus, uncertainty must be accounted for when 
conducting economic evaluations.  
Uncertainty includes first order uncertainty owing to structural uncertainty associated 
with assumptions made in the model, random variability in outcomes between identical 
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patients, and uncertainty surrounding parameter estimates employed [14]. Structural 
uncertainty can be examined using sensitivity analysis, for example scenario analyses 
can be used to examine the impact of the assumptions used. Parameter uncertainty 
can be examined using deterministic sensitivity analysis also. For large models with 
correlated parameters etc. probabilistic sensitivity analyses are more practical. These 
provide a means of addressing joint uncertainty in a model. By incorporating 
uncertainty from input parameters, uncertainty on output parameters can be described 
[14]. To conduct a probabilistic sensitivity analysis, uncertainty in input parameters 
need to be characterized first. This uncertainty is propagated through the model using 
a Monte Carlo simulation. The implications of uncertainty can then be presented [14]. 
Presenting Cost Effectiveness Results 
Cost Effectiveness Plane 
A Cost Effectiveness (CE) Plane is a four-quadrant diagram that illustrates the 
incremental costs and effects of an intervention compared to an alternative [19]. The 
incremental costs are plotted on the vertical axis and the effects on the horizontal axis. 
Figure 1 presents an example of a CE plane. If the intervention is more effective i.e. 
generates more benefit and is less costly than the comparator its point estimate will 
fall in the Southeast quadrant. Here the intervention is considered cost effective and 
is dominant. Alternatively, if the intervention less effective i.e. generates less benefit 
and is more costly its point estimate will fall in the Northwest quadrant. Here the 
intervention is not considered cost effective and is dominated. Where the intervention 
is more effective and more costly its point estimate will fall in the Northeast quadrant. 
An estimate of what society is willing to pay for the additional unit of effectiveness is 
required to determine if the additional benefit is worth the additional cost. If the 
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intervention is less effective and less costly its point estimate will fall in the Southwest 
quadrant.  
Where a probabilistic sensitivity analysis has been performed the results of the 
simulation will yield a large number of points, which can be plotted in a similar fashion 
to what is shown in Figure 1. The distribution of these points amongst the four 
quadrants illustrates the existence and extent of uncertainty in incremental costs and 
effects. These results are represented by the ‘cloud’ of points on Figure 2.  
Incremental Cost Effectiveness Ratio (ICER) 
The Incremental Cost Effectiveness Ratio (ICER) provides a measure of additional 
cost per additional unit of health gain produced by the intervention compared to its 
comparator in CEAs and CUAs. The ICER is estimated as the additional cost (ΔC) of 
the intervention compared to its comparator divided by the additional health gain or 
benefit (ΔE); ICER: ΔC / ΔE [20]. Where a probabilistic sensitivity analysis is 
performed the average of the expected benefits and costs can be used to estimate the 
ICER.  
The ICER can be compared to an external threshold value or ceiling ratio (RT), which 
represents the maximum society is willing to pay for an additional unit of effect or 
health gain. The diagonal dashed line on figure 1 presents this cost effectiveness 
threshold with the slope of a line drawn between the origin and point A i.e. OA 
representing the ICER. Figure 1 shows that the ICER associated with point A is less 
than the threshold so this intervention can be considered cost effective.  
Incremental Net Benefit  
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The incremental net benefit (INB) is an alternative to the ICER. In CBAs, the INB can 
be estimated straight forwardly as both the costs and benefits are measured in 
monetary amounts. In CEAs or CUAs however the benefits need to be translated into 
monetary amounts.  This can be done using the ceiling ratio. Previously, if ΔC / ΔE < 
RT the intervention is cost effective. If we re-arrange the formula it can be said that 
the intervention is cost effective if the INB is positive. The INB is the change in effects 
multiplied by the ceiling ratio less additional costs; ICER, RT * ΔE - ΔC < 0. For the 
net benefit to be positive the monetary benefit must be greater than additional costs; 
RT * ΔE < ΔC. 
Cost Effectiveness Acceptability Curve (CEAC) 
CEACs summarise uncertainty surrounding the cost effectiveness decision for various 
ceiling ratios [21-23]. Recalling from the ICE Plane, co-ordinates that fall below and to 
the right of the line, representing the ceiling ratio, indicate the intervention is cost 
effective compared to the comparator. When a probabilistic sensitivity analysis is 
employed, the Monte Carlo simulation yields multiple co-ordinates. When these are 
plotted the probability of the technology being cost effective can be estimated as the 
number of co-ordinates falling in this region as a proportion of the simulation size. This 
can be repeated for all potential ceiling ratio values to represent different willingness 
to pay thresholds. The probability of the intervention being cost effective associated 
with each ceiling ratio is plotted on the CEAC. For example, if on an ICE Plane at a 
ceiling ratio of €45,000/QALY, 6% of the co-ordinates lie in the cost effectiveness 
region then there would be a 6% probability that the intervention is cost effective and 
a 94% probability that the alternative is cost effective. This is repeated for a range of 
ceiling ratio values and plotted to form the CEAC.  Figure 3 illustrates this example. 
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Discussion 
Challenges in Implementing Economic Evaluations and/or Health Technology 
Assessments in Ophthalmology 
The methods described above are standard methods employed to conduct economic 
evaluations. They are robust and verified. However, a ‘one-size-fits-all’ approach may 
not apply. Individual clinical and therapeutic areas must consider how to implement 
them.  A key challenge is the sensitive measurement of health outcomes in a 
meaningful way particular to a clinical or therapeutic area.  
Kymes [24] questioned how deteriorating vision and its impact on quality of life should 
be measured appropriately. Furthermore, given their sensitivity and responsiveness, 
the suitability of existing generic quality of life instruments like EQ-5D, to measure the 
impact of vision and its deterioration on quality of life has been debated [24, 25]. Others 
[26] were concerned with how to measure quality of life over the duration of a disease 
– particularly when quality of life may be impacted greater in the later stages of 
diseases. They also had concerns with respect to gathering evidence with ethical 
concerns regarding the use of randomized controlled trials and the procurement of 
sufficient sample sizes [26]. 
Opportunities for Implementing Economic Evaluations and/or Health 
Technology Assessments in Ophthalmology 
The challenges surrounding measuring quality of life over the lifetime of a disease or 
for a particular patient population such as the visually impaired and collecting evidence 
are not unique to ophthalmology.  Similar data collection issues are present in many 
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clinical and therapeutic areas – particularly where non-drug interventions are being 
considered.  
While the economic evaluation techniques discussed in this primer are predominately 
associated with drugs their foundations go beyond this. The incorporation of decision 
analytical modelling provides a means of overcoming some of the challenges listed 
above. This permits the extrapolation of data beyond that observed in trials, linkage of 
intermediate clinical endpoints to final outcomes, the generalisation of outcomes to 
other settings and the synthesis of head-to-head comparisons where relevant trials 
are non-existent thereby offering a means to inform decisions in the absence of mature 
data [12]. 
Likewise, measuring health outcomes so that they are sensitive has been experienced 
in many areas, including mental health. Often condition specific instruments are 
mapped onto generic ones, such as VFQ-25. While this is not the ideal it is suitable 
and attempts have been made to do this in ophthalmology [27, 28]. 
The Food and Drug Administration Agency (FDA) and other regulators have ensured 
that drug interventions have sufficient evidence to populate economic models. 
Provisions to extend this to medical devices are underway. Prior to this, assessments 
of medical devices were limited to using evidence from early cases, registries etc. This 
evidence was synthesized and extrapolated to estimate cost effectiveness using 
decision analytical modelling. Such a strategy can be adopted for ophthalmological 
health care interventions as health technology assessments (HTAs) develop.  
It has been suggested that ophthalmological economic evaluations and HTAs 
incorporate synergies created from simultaneously screening for multiple diseases in 
primary care; as well as patient preferences and simultaneously consider the cost 
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effectiveness of preventative care [24]. Capturing and valuing such synergies, along 
with incorporating preventative care and patient preferences are priorities for all clinical 
areas. There is an opportunity for ophthalmology to lead the way in how to achieve 
these priorities.  
 
Conclusions 
The challenges facing health care systems worldwide - changing demographics, a 
rapid pace of change and the development of new technologies are only going to 
intensify. While ophthalmology has come to the table later with respect to requirements 
for formal economic evaluations it has not been immune to budget cuts etc.  
Ophthalmology needs to be ready and able to engage with health economists to 
prepare, interpret, critically evaluate and use findings of economic evaluations and 
health technology assessments. 
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Figure 1. A cost effectiveness (CE) plane is a four-quadrant diagram that illustrates 
the incremental costs and effects of an intervention compared to an alternative. The 
incremental costs are plotted on the vertical axis and the effects on the horizontal axis.  
Figure 2. The incremental cost effectiveness (ICE) plane is four quadrant diagram that 
plots uncertainty surrounding costs and effects of an intervention compared to its 
alternative. Where a probabilistic sensitivity analysis has been performed the results 
of the simulation will yield a number of points, which can be plotted in a similar fashion 
to what is shown in figure 1. The distribution of these points amongst the four 
quadrants illustrates the existence and extent of uncertainty in incremental costs and 
effects. These results are represented by the ‘cloud’ of points (using results of the 
Monte Carlo simulation).  
In this example, there is no uncertainty surrounding the existence of differences in 
costs, intervention is more expensive than current practice. But there is uncertainty 
surrounding the extent of this uncertainty; additional costs vary between €18 and €708 
(vertical axis). There is uncertainty surrounding the existence and extent of differences 
in effects with additional benefits varying between -0.06 and +0.05 QALYs (horiztonal 
axis).  
Figure 3. Cost effectiveness acceptability curves summarise the uncertainty 
surrounding the cost effectiveness decision for various ceiling ratios using the Monte 
Carlo simulation results (presented on the CE plane) results. For example, if on the 
ICE plane at a ceiling ratio of €45,000/QALY, 6% of the co-ordinates lie in the cost 
effectiveness region then there would be a 6% probability that the intervention is cost 
effective and 94% probability that current practice is cost effective. This is repeated 
for a range of ceiling ratio values and plotted to form the CEAC.    
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Figure Legend 
Figure 1. The Cost-Effectiveness Plane 
 
 
Figure 1. A cost effectiveness (CE) plane is a four-quadrant diagram that illustrates 
the incremental costs and effects of an intervention compared to an alternative. The 
incremental costs are plotted on the vertical axis and the effects on the horizontal axis.  
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Figure 2. Sample Cost Effectiveness Plane from Probabilistic Sensitivity 
Analysis 
 
 
Figure 2. The incremental cost effectiveness (ICE) plane is four quadrant diagram that 
plots uncertainty surrounding costs and effects of an intervention compared to its 
alternative. Where a probabilistic sensitivity analysis has been performed the results 
of the simulation will yield a number of points, which can be plotted in a similar fashion 
to what is shown in figure 1. The distribution of these points amongst the four 
quadrants illustrates the existence and extent of uncertainty in incremental costs and 
effects. These results are represented by the ‘cloud’ of points (using results of the 
Monte Carlo simulation).  
In this example, there is no uncertainty surrounding the existence of differences in 
costs, intervention is more expensive than current practice. But there is uncertainty 
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surrounding the extent of this uncertainty; additional costs vary between €18 and €708 
(vertical axis). There is uncertainty surrounding the existence and extent of differences 
in effects with additional benefits varying between -0.06 and +0.05 QALYs (horiztonal 
axis).  
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Figure 3. Sample Cost Effectiveness Acceptability Curve 
 
Figure 3. Cost effectiveness acceptability curves summarise the uncertainty 
surrounding the cost effectiveness decision for various ceiling ratios using the Monte 
Carlo simulation results (presented on the CE plane) results. For example, if on the 
ICE plane at a ceiling ratio of €45,000/QALY, 6% of the co-ordinates lie in the cost 
effectiveness region then there would be a 6% probability that the intervention is cost 
effective and 94% probability that current practice is cost effective. This is repeated 
for a range of ceiling ratio values and plotted to form the CEAC.   
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Supplementary Material  
Table 1. PubMed Search Hits 
  
 
Search Terms 
 
Cost/resource/cos
t effective/cost 
utility 
 
Cost 
effective/cost 
utility 
 
Cost/resource 
Search period 1966-
2016 
% 2009-
2016  
1966-
2016 
% 2009-
2016 
1966 -
2016 
% 2009-
2016 
Glaucoma 
1,032 50% 265 52% 1032 50% 
Cataract 
1,388 44% 281 45% 1,388 44% 
Diabetic 
retinopathy 
794 51% 245 44% 794 51% 
Macular 
degeneration 
754 64% 260 57% 754 64% 
Glaucoma, 
Cataract, Diabetic 
Retinopathy and 
Macular 
degeneration 
3,491 48% 945 48% 3,491 49% 
 
 
 
 
